# **Titlepage**

# Baseline TyG index, myoglobin, and cerebral infarction history predict the onset of pulmonary hypertension in coronary artery disease patients after PCI treatment within a median of 4.5 years: a prospective cohort study

- Li Xie<sup>1</sup>, Shilin Fu<sup>1</sup>, Yuzheng Xu<sup>1</sup>, Litong Ran<sup>1</sup>, Jing Luo<sup>1</sup>, Rongsheng Rao<sup>2</sup>, Jianfei Chen<sup>1</sup>, Shi-Zhu Bian<sup>1\*</sup> and Dehui Qian<sup>1\*</sup> 1
- 2
- <sup>1</sup>Institute of Cardiovascular Diseases of PLA; Department of Cardiology, Xinqiao Hospital, Army 3
- Medical University (Third Military Medical University). 4
- <sup>2</sup>Department of Ultrasonography, Xinqiao Hospital, Army Medical University (Third Military 5
- 6 Medical University).
- 7 \* Correspondence authors:
- Shi-Zhu Bian 8
- 9 bianshizhu@163.com
- 10 Dehui Qian
- 11 qiandehui@163.com
- 12 Short running title: Baseline TyG predicts PH
- 13 The number of the words of abstract: 247.
- 14 The number of the word of main text: 3274.
- 15 References: 46.
- 16 Tables:5.

- 17 Keywords: TyG index; pulmonary hypertension; coronary artery disease; percutaneous
- coronary intervention; echocardiography 18

**Abstract** 

20

38

21 **Aim:** To identify the predictive role of the TvG index for the onset of pulmonary hypertension in patients with coronary artery disease (CAD) who underwent percutaneous coronary intervention 22 23 (PCI) treatment. **Methods:** We performed this prospective cohort study among CAD patients who 24 received PCI treatment in our center from July 2016 to October 2022. The baselines of 25 echocardiography at both cross-sections and blood biomarkers. A coronary angiography operation was also performed. Within a median of 4.5 years of follow-up, the patients underwent 26 27 echocardiography to measure their pulmonary hypertension (PH). Results: Baseline BNP was 28 statistically higher in the PH patients (p = 0.007). The baseline myoglobin (MYO), was significantly 29 higher among PH patients (p < 0.001). Though the glucose level showed no difference between PH 30 and non-PH groups, the HDL-C was in a lower level in the PH group (p = 0.033). However, TyG index showed no differences between PH and non-PH groups [6.95 (6.47-7.36) vs. 7.15 (6.49-7.96), 31 32 p = 0.202]. In the univariate regression, cerebral infarction history, right atria end-diastolic internal 33 diameter, MYO, triglyceride, HDL-C and TvG index (p < 0.05) were potential predictors for PH. 34 Finally, the adjusted logistic regression indicated that cerebral infarction history (p = 0.39), MYO (p35 = 0.044) and TyG index (p = 0.048) were independent predictors of the onset of PH. Conclusion: PH 36 is prevalent in CAD patients after PCI treatment. The baseline TyG index, cerebral infarction history, 37 and MYO level were independent predictors for PH in CAD patients after PCI treatment.

### 1 Introduction

39

- 40 Insulin resistance (IR) has been considered a critical pathophysiological process in cardiometabolic
- 41 diseases and other cardiovascular diseases in various clinical and basic research (1,2). The
- 42 triglyceride-glucose (TyG) index is the product of fasting plasma glucose (FPG) and triglycerides
- 43 (TGs). It has been indicated to be a reliable surrogate marker of IR (3,4). Furthermore, it has been
- indicated that the TyG index is well-correlated to the homeostasis model which is used to assess IR
- 45 (2,5,6). It has also been used as a marker and predictor for a variety of diseases, including major
- adverse cardiovascular events (MACE) as well as atrial fibrillation (AF), over traditional risk factors
- 47 (5,7-9). The TyG index has been used widely because IR is a leading reason for the elevations of
- 48 triglyceride and glucose among healthy populations.
- 49 Among ST elevation myocardial infarction patients, the higher TyG index has been indicated to
- 50 increase the risk of major adverse cardiac and cerebrovascular events(7,10,11). Although a number of
- 51 the previous studies have indicated the associations between TyG index and vascular diseases, no
- 52 studies further identify the predictive role of the TyG index in pulmonary hypertension (PH) among
- coronary artery disease (CAD) patients after PCI treatment (9,12-14).
- 54 The complications of CAD patients after PCI such as MACE and heart failure have received
- sufficient attention (15-18). However, the effect of CAD on pulmonary circulation has not been
- investigated widely, especially after patients received PCI treatment (19,20).
- 57 PH has been considered as one of the most common complications in patients with cardiovascular
- diseases. PH is characterized with an elevated pulmonary arterial pressure (PAP) and significant
- remodeling of pulmonary arterioles (21-23). PH is a clinical syndrome which is caused by various
- etiologies resulting in modifications of function or structures of pulmonary vasculature, leading to the
- rise of PAP and pulmonary vascular resistance (PVR) (21). It has been indicated that PH is the
- 62 primary reason for right heart failure, which may be a fatal complication in patients with
- cardiovascular disease. The incidence of PH in various cardiovascular diseases has been reported to
- be from 20 to 80%. Except in cases of congenital heart disease and dilated cardiomyopathy, PH was
- 65 frequently found in CAD patients (19). Recently, PH has also been recognized as a threat in
- cardiovascular patients which may lead to fatigue, shortness of breath and even right heart failure and
- death. Because the onset of PH among patients is often obscured by other diseases, when PH is
- diagnosed, it may be in its later stage and difficult to treat. Thus, the early discovery and diagnosis of
- 69 PH is of great importance (24).
- 70 It is well known that PH is a multi-factorial and complex clinical syndrome which accompanies a
- variety of diseases including heart failure, lung diseases, hypoxia and chronic thromboembolism
- 72 (22). PH in CAD patients after PCI has not been identified (25). We designed this study to identify
- 73 the predictive role of the TyG index in PH populations who suffers from CAD patients after PCI
- 74 operation treatments.

### 2 Methods

75

76

### 2.1 Patients and Study Design

- All consecutive patients who were clinically diagnosed with CAD in our center from July 2016 and
- 78 July 2019 were included into this study according to the inclusion and exclusion criteria. The follow-
- 79 up was finished in October 2022. The inclusion criteria were: aged from 18-80 years, and clinically
- 80 diagnosed with unstable angina. A patient with one of the following diseases including aortic

- 81 aneurysm, chronic kidney diseases, infections, congenital heart diseases, cardiac valve diseases,
- 82 connective tissue diseases, and cancer. A patient who has received PCI or coronary artery bypass
- 83 graft previously has also been excluded.
- 84 Finally, a total of 247 patients with CAD were enrolled. Upon admission, the patients' laboratory and
- 85 demographic data as well as the disease' history have been tested and recorded. Our study conforms
- to the Declaration of Helsinki. The study has been approved by our ethical committee of Xingiao 86
- 87 Hospital, Third Military Medical University (Army Military Medical University). The patients were
- 88 familiarized with the procedure and contents of the study and provided written informed consent.
- 89 Venous blood samples were obtained from patients on admission prior to coronary intervention. Both
- 90 serum and plasma samples were obtained and placed on ice. After they were centrifuged within 30
- 91 min, they were stored at -70 °C for the further test.

#### 92 The Assessments of CAD Severity for each patient

- 93 We have performed a scheduled coronary angiography (CAG) for each patient according to standard
- 94 techniques. At least two of our trained interventional cardiologists. CAD in our center was defined as
- 95 following: at least a single-vessel with a stenosis >50%.

#### 96 2.3 **Biochemical Parameters**

- 97 We have obtained venous blood samples from CAD patients in the early morning after at least 12
- 98 hours' overnight fast.
- 99 We have performed the biochemical examinations. We have tested the levels of blood glucose
- (fasting blood glucose, FBG) and lipids including total cholesterol (TC), high-density lipoprotein 100
- 101 cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG)
- 102 concentrations by using Beckman Coulter AU5800 system (USA). Furthermore, we have also
- 103 detected the liver and renal functions with the same machine above.
- 104 We have also measured the plasma UA with Roche enzymatic assays (Roche Diagnostics GmbH,
- 105 Mannheim, Germany). Furthermore, plasma creatinine (Cr) concentration was also measured by
- 106 using Hitachi 7600 autoanalyzer (Hitachi, Tokyo, Japan) via enzymatic assay. The blood urea
- 107 nitrogen concentration (BUN) was also measured (FERENE methods, Beckman AU5821).
- Finally, we have tested the electrolytes including sodium concentration (Na<sup>+</sup>), serum calcium 108
- concentration (Ca<sup>2+</sup>), phosphate concentration (P), serum potassium concentration (K<sup>+</sup>) and chloride 109
- 110 ion (Cl-) were also measured.
- The levels of myohemoglobin (MYO), creatine kinase isoenzyme-MB (CK-MB) and cardiac 111
- 112 troponin I (TnI) in serum were measured using standard assay kits and a Geteln 110 (Jiangsu, China)
- 113 automatic chemiluminescence immunoassay analyzer, and the plasma level of brain natriuretic
- 114 peptide (BNP) was also measured according to the manufacturer's instructions using a Geteln 110
- 115 (Jiangsu, China) automatic chemiluminescence immunoassay analyzer.

#### 2.4 Clinical data collection

- The patients were followed-up by our physicians. We used a standardized self-report questionnaire 117
- 118 form to record patients' data including demographic information and diseases history as well as the
- 119 medication use. Height and weight were also measured. The history of smoking status and drinking.

- 120 The systolic blood pressure (SBP), heart rate (HR) and diastolic blood pressure (DBP) were
- 121 measured on the right arm in a sitting position after sufficient rest.

#### **Echocardiography examinations** 122

- 123 Both at the baseline and follow-up cross-sections, echocardiography examinations have been
- 124 performed by our trained technicians with an ultrasonography workstation (CX50, Philips, USA;
- 125 probe: S5). The patients were positioned in a supine position after a rest of ten min. The technicians
- have measured and recorded the end-diastolic internal diameters of the left and right atria (LAD and 126
- 127 RAD). As regulation, the end-diastolic internal diameters of left and right ventricles (LVDD and
- 128 RVD) have also been measured and recorded. In the next step, the thickness of the interventricular
- 129 septum (IVS) and left ventricular posterior wall (LVPW) have also been evaluated and recorded. The
- 130 fractional shortening (FS), stroke volume (SV) and ejection fraction (LVEF) has been measured and
- 131 calculated. Finally, the tricuspid regurgitation area (TRA), TR velocity (TRV) which was used to
- 132 calculate the PAP, and TR pressure.

#### 133 2.6 Variables

- 134 We measured and calculated the systolic PAP (sPAP) by using the modified Bernoulli equation using
- 135 the tricuspid systolic jet according to the American Society of Echocardiography:

$$sPAP = 4 \times (TRV)^2 + estimated right atrial pressure$$

- The estimated right atrial pressure was recorded as 5 mmHg (normal right atrium size), 10 mmHg 136
- 137 (mildly enlarged right atrium size), and 15 mmHg (significantly enlarged right atrium size) in
- 138 according to the right atrium size.
- 139 An sPAP >35 mmHg was defined as PH. In contrast, the patients with sPAP <35 mmHg were
- 140 included in the non-PH group According to the American Society of Echocardiography and other
- 141 studies.

147

#### 142 Follow-up 2.7

- 143 The follow-up at the outpatient department was performed by our doctors, including Li Xie, Shi-Zhu
- 144 Bian, Dehui Qian, Shilin Fu and Jianfei Chen, with an objective case report form, and regular
- 145 examinations for the CAD patients. Furthermore, the examination of echocardiograms was performed
- 146 by a technician, Dr. Rongsheng Rao.

### **Statistical Analysis**

- 148 All of our statistical analyses were employed with SPSS software (version 26.0, IBM Corp.,
- 149 America). Continuous normalized distribution variables are expressed as mean  $\pm$  standard deviation
- 150 (SD) and were compared using Students' test between two groups. The non-normalized distributed
- 151 data are summarized as medians (interquartile ranges). Each categorical variable was expressed in
- 152 case and proportions. The differences of the non-normalized distributed data between the PH group
- 153 and non-PH group were analyze by using a Kruskal-Wallis nonparametric test. The correlations
- 154 between baseline parameters and sPAP were identified by using Spearman's correlation analyses.
- 155 The potential predictors were analyzed by univariate and multivariate regressions. The backward
- 156 stepwise logistic regression models were used to identify the predictors for the onset of PH in CAD
- 157 patients. Statistical significance was defined as a p value is less than 0.05.

#### 3 **Results**

158

- Within a median of 4.5 years' follow-up, the incidence of PH was 8.91%. The demographic data 159
- 160 were shown in table 1. The LAD and LVDD increased dramatically while the LVEF decreased
- significantly (p < 0.001). Furthermore, the right heart structure also changed significantly (table 2). 161
- 162 However, at the baseline cross-section, no significant differences were found between the PH and
- 163 non-PH groups among LAD, LVDD, RAD, RVD, LVEF and SV (all p values are greater than 0.05).
- 164 The biomarker of heart failure, BNP, was dramatically higher in the PH population than in the non-
- 165 PH ones (68.00 [18.05-196.00] vs. 174.00 [76.25-447.75], p = 0.007). The biomarkers for cardiac
- 166 injury, including TNI and CK-MB, showed no significant differences between PH and non-PH
- 167 groups (p > 0.05). However, baseline MYO was dramatically higher in the PH group than that in the
- 168 non-PH populations (56.30 [42.65-77.25] vs.76.30 [64.38-126.35] ng/ml, p < 0.001). We also found
- 169 that HDL-C (1.06 [0.870-1.26] vs. 0.915 [0.770-1.071] mmol/L) was significantly lower in the PH
- 170 group than that in the non-PH group (p = 0.033). However, the TyG index showed no significant
- 171 difference between PH patients and non-PH ones (6.95 [6.47-7.36] vs. 7.15 [6.49-7.96], p = 0.202).
- The basic parameters, including HR, SBP and DBP, showed similar levels between PH group and 172
- 173 non-PH group (p > 0.05) (table2-3).
- 174 In the next step, we analyzed the correlation between sPAP and all of the parameters. The
- 175 demographic variables, including BMI and age, showed no close association with sPAP. Whilst we
- 176 found that the baselines of TRA (r = 0.151, p = 0.017) and TRV (r = 0.156, p = 0.014) were
- 177 significantly positively correlated with sPAP, other baseline hemodynamics parameters showed no
- 178 close relationship with sPAP (table 4).
- 179 In the univariate regression, we performed analyses with each variable. We identified that cerebral
- 180 infarction history ( $\beta = 0.991$ , odds ratio (OR): 2.694, 95% confidence interval (CI): 1.085-6.690, p =
- 0.033), LAD ( $\beta$  = 0.074, OR: 1.077, 95% CI: 0.987- 1.174, p = 0.095), RAD ( $\beta$  = 0.055, OR: 1.057, 181
- 182 95% CI: 0.976-1.144, p = ), MYO ( $\beta = 0.007$ , OR: 1.007, 95% CI: 1.001-1.013, p = 0.024), TG ( $\beta =$
- 183 0.304, OR: 1.355, 95% CI: 1.062-1.730, p = 0.015), HDL-C ( $\beta$  = -1.744, OR: 0.175, 95% CI: 0.027-
- 184 1.115, p = 0.065), HbA1c ( $\beta$  = 0.288, OR: 1.334, 95% CI: 0.975-1.825, p = 0.071) and TyG index ( $\beta$
- 185 = 0.628, OR: 2.389, 95% CI: 1.308-4.363, p = 0.005) were potential predictors/risk factors for PH in
- 186 CAD patients after PCI treatment (table 5).
- 187 Finally, the adjusted logistic regression indicated that cerebral infarction history ( $\beta = 0.990$ , OR:
- 188 2.690, 95% CI: 1.054-6.871, p = 0.039), MYO ( $\beta = 0.006, OR: 1.006, 95\%$  CI: 1.000-1.012, p = 0.039)
- 189 0.044), and TyG ( $\beta$  =0.636, OR: 1.889, 95% CI: 1.006-3.546, p = 0.048) were independent predictors
- 190 of the onset of PH (table 6).

#### 191 4 **Discussion**

199

- 192 We performed a prospective cohort study within a median of 4.5 years' follow-up. The primary
- 193 endpoint focused on the onset of PH, which is frequently accompanied with various cardiovascular
- 194 diseases. However, there have been few studies focusing on PH in CAD patients who have received
- 195 PCI treatment. We analyzed the associations between the baselines of demographic data, renal
- 196 functions, biomarkers for cardiac injury, serum lipids, and glucose. We have identified that the
- 197 history of cerebral infarction, the TyG index baseline, and the MYO baseline were independent
- 198 predictors for PH in CAD patients who received PCI treatment after 4.5 years.

#### 4.1 PH in CAD patients after treatment with PCI

- 200 According to the previous guidelines and studies, PH refers to mean PAP (mPAP) >25mmHg at sea
- 201 level measured by right heart catheterization (22). However, in the latest guidelines, the cutoff value
- 202 of mPAP for PH has been updated to 20 mmHg, which may include more PH patients who were not
- 203 diagnosed as PH in the past (22). Thus, a higher incidence of PH will be diagnosed in various
- 204 diseases, and the early diagnosis and prevention of PH will prevent it developing into the advanced
- 205 stage. The importance of PH in various cardiovascular diseases has been promoted. However, the
- 206 diagnosis of PH evaluated by echocardiography has not yet been updated (26). Thus, in our present
- 207 study, the cutoff of sPAP measured by echocardiography had not been revised and updated, and
- needs to be further studied in clinical practice. In future studies, we may investigate PH in 208
- 209 accordance with the latest guidelines for the cut-off of sPAP evaluated by non-invasive
- 210 echocardiography.
- 211 In our present study, the PH which accompanied CAD may be classified as PH due to left heart
- 212 diseases (19,22,27). Left heart-related diseases are one of the most frequent causes of PH. However,
- 213 the clinical prevalence data of left heart disease-related PH has not been uncovered (19.27). The
- 214 incidence of PH has varied in different studies due to differing evaluation methods and criteria for
- 215 PH diagnosis.

224

242

- 216 As discussed above, PH has been recognized as one of the most frequent complications of various
- 217 cardiovascular diseases (28-31). However, in CAD patients, few studies have focused on PH
- 218 complications. Incidence of PH was 8.91% among 247 CAD patients who received PCI treatment in
- 219 our study. This incidence may be much higher if the cutoff is updated in the future (22). Though PH
- 220 was not as significant as heart failure in CAD patients, it may affect right heart function or induce
- 221 symptoms. PH is a common complication of CAD patients which has previously not been widely
- 222 investigated and treated. Thus, PH should be given sufficient attention in clinical practice for CAD
- 223 patient treatment and management.

#### 4.2 Association of IR/TyG index and cardiovascular diseases

- 225 It has been indicated that IR is involved in the pathogenesis of various of diseases including
- 226 atherosclerotic cardiovascular diseases (2). Diabetes is considered a primary risk factor of
- 227 cardiovascular diseases, however, the association between diabetes and PH has not been confirmed
- 228 (32). Though IR has been widely indicated to be a risk factor for a number of cardiovascular diseases
- 229 including MACE and atherosclerosis (1,2,12,33), few studies have reported the roles of IR in PH,
- 230 especially in CAD patients. The novel TyG index, a simple surrogate marker of IR, has been widely
- 231 used as a marker/risk factor/predictor for a large number of cardiovascular diseases (5,34-36). A
- 232 higher TyG index has been indicated to be correlated to hypertension (37). They found that the
- 233 hypertension was significantly more likely in the patients with the highest level of TyG index than in
- 234 the lowest level of TyG index patients (38). However, these results should be studied in future large-
- 235 scale prospective cohort studies. In addition, further studies are needed to elucidate the potential
- 236 pathophysiological mechanisms underlying the association between the TyG index and hypertension.
- 237 Increasing evidence indicates that a higher TyG index or a higher level of TG and FBG levels
- 238 increase atherosclerosis risk, including peripheral artery disease and arterial stiffness (39).
- 239 Triglycerides have been indicated to be independent risk factors for CVD. Uncontrolled diabetes
- 240 and/or hyperlipidemia has been indicated to result to high level of TyG index, which is associated
- 241 with symptomatic patients' CVD (35).

#### 4.3 TyG and PH in CAD patients after PCI treatment

- 243 Few researchers have focused on the complications of pulmonary vessels. Though PH has attracted
- 244 an increasing amount of attention from clinical physicians and researchers, PH's clinical
- 245 characteristics and risk factors in CAD patients who have received PCI treatment have not been
- widely investigated (19.20.24.25.40). The roles of the TvG index in outcomes of patients who 246
- 247 underwent PCI treatment have been partly reported (7,10,41,42). The associations between TyG
- 248 index and poor prognosis in patients with acute ST-elevation myocardial infarction after PCI have
- 249 also been indicated in previous studies (7,10). However, the potential role of the TyG index as a
- 250 predictor of PH in CAD patients after PCI treatment has not been studied. Thus, we focused on the
- 251 predictive role of baseline TyG for PH in CAD patients who have received PCI treatment, within a
- 252 median of 4.5 years' follow-up. In the present study, PH patients were indicated to be characterized
- 253 with a higher level of TyG index, but this was not statistically significant. In the univariate
- 254 regression, we found that the TyG index was a potential predictive factor of PH. Additionally, the
- 255 adjusted regression indicated that the higher baseline TyG index was an independent predictor for the
- 256 onset of PH in CAD patients who underwent PCI treatment. Though no evidence indicated that PH is
- 257 caused by IR or abnormal metabolism of lipids or glucose, PH may be the results of IR in
- 258 cardiovascular diseases (1,2). The patients in our study were CAD patients who may have also
- 259 suffered from left heart failure, and the PH found may have been caused by this left heart failure.
- 260 Another possibility is that the IR or TyG index may be associated with PH via its roles in the heart or
- 261 coronary arteries (43-45). Furthermore, it is also possible that IR has a detrimental effect on
- 262 pulmonary vessels, increasing the remodeling of pulmonary vessels and PVR (44,45).
- 263 In clinical practice, a physician usually examines fasting glucose level to identify patients with high-
- 264 risk, especially cardiovascular disease patients (11,46). The TyG index may also be valuable for
- 265 prognostic cardiovascular disease risk stratifications, and may have a higher diagnostic significance
- 266 than FBG and TG levels (11,46). However, PH has been indicated to be a progressively and
- 267 dynamically progresses disorder. Thus, the TyG index as a prognostic marker can be easily biased by
- 268 hyperlipidemia and diabetes.

269

280

283

284

### Other predictors for PH in CAD patients

- 270 It is of great importance to identify the risk factors/predictors of PH as a prognosis of CAD patients
- 271 who underwent PCI treatment for effective prevention. We have identified that beside the TyG index,
- 272 the history of cerebral infarction and the baseline level of MYO were also independent predictors for
- 273 PH in CAD patients. To the best of our knowledge, this is the first study to identify that the history of
- 274 cerebral infarction was an independent risk factor for PH in CAD patients. This may be explained by
- 275 the comorbidity of CVD and PH. It is worth noting that some of the patients included in our study
- 276 were at risk of CAD because they had a previous history of CVD. Furthermore, baseline MYO was
- 277 also indicated to be an independent risk factor for the onset of PH in CAD patients after PCI
- 278 treatment. The above results suggest that myocardial injury may lead to chronic left heart failure,
- 279 which is a common reason for PH.

#### 5 Conclusion

- PH is prevalent in CAD patients after PCI treatment. The baseline TyG index, cerebral infarction 281
- 282 history, and MYO level were independent predictors for PH in CAD patients after PCI treatment.

#### 6 **Conflict of Interest**

Baseline TyG predicts PH We declare that the research was conducted without any commercial or financial relationships that 285 286 could be construed as a potential conflict of interest. 287 **Author Contributions** 7 288 DQ and SZB participated in the design of the study. The manuscript and the statistical analyses were 289 performed by LX, DQ and SZB. DQ reviewed and revised this manuscript critically for important 290 intellectual content. Echocardiography examinations were performed by our technician RR. The 291 sPAP-related assessments were recorded and analyzed by YX and LX. Clinical data and laboratory 292 examinations data were performed and recorded by LX, LR and JL. Other laboratory data and 293 patients' follow-up were carried out by JC, YX and SF. The CAG operations were performed by LX, 294 JC and DO. 295 8 **Funding** 296 The present research is supported by the "Senior Medical Talents Program of Chongqing for 297 Yong and Middle-aged" to Shi-Zhu Bian, "Miaopu" Young Scientists Program from Army Military Medical University (2019R046) and Basic Research Program from Army Military 298 299 Medical University (2020D050). 300 9 **Acknowledgments** 301 The authors would like to thank all the individuals who participated in this study for their supports. 302 303 References 10 [1] R. Rojas-Humpire, M. Olarte-Durand, S. Medina-Ramirez, R. Gutierrez-Ajalcrina, J.F. Canaza, and S. Huancahuire-Vega, Insulin Resistance Indexes as Biomarkers of Lifetime Cardiovascular Risk among Adults from Peru. J Nutr Metab 2021 (2021) 6633700. [2] M.A. Hill, Y. Yang, L. Zhang, Z. Sun, G. Jia, A.R. Parrish, and J.R. Sowers, Insulin resistance,

- 304
- 305
- 306
- 307
- 308 cardiovascular stiffening and cardiovascular disease. Metabolism 119 (2021) 154766.
- 309 [3] H. Li, Y. Zuo, F. Qian, S. Chen, X. Tian, P. Wang, X. Li, X. Guo, S. Wu, and A. Wang,
- 310 Triglyceride-glucose index variability and incident cardiovascular disease: a prospective cohort
- 311 study. Cardiovasc Diabetol 21 (2022) 105.
- 312 [4] Q. Zhao, T.Y. Zhang, Y.J. Cheng, Y. Ma, Y.K. Xu, J.Q. Yang, and Y.J. Zhou, Triglyceride-
- 313 Glucose Index as a Surrogate Marker of Insulin Resistance for Predicting Cardiovascular Outcomes

- 314 in Nondiabetic Patients with Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing
- 315 Percutaneous Coronary Intervention. J Atheroscler Thromb 28 (2021) 1175-1194.
- [5] S.P. Araujo, L.L. Juvanhol, J. Bressan, and H.H.M. Hermsdorff, Triglyceride glucose index: A 316
- 317 new biomarker in predicting cardiovascular risk. Prev Med Rep 29 (2022) 101941.
- 318 [6] X. Zeng, D. Han, H. Zhou, Y. Xue, X. Wang, Q. Zhan, Y. Bai, X. Huang, Q. Zeng, H. Zhang, Z.
- 319 Ma, H. Ren, and D. Xu, Triglyceride-Glucose Index and Homeostasis Model Assessment-Insulin
- 320 Resistance in Young Adulthood and Risk of Incident Congestive Heart Failure in Midlife: The
- 321 Coronary Artery Risk Development in Young Adults Study. Front Cardiovasc Med 9 (2022) 944258.
- 322 [7] Y. Ling, C. Fu, O. Fan, J. Liu, L. Jiang, and S. Tang, Triglyceride-Glucose Index and New-Onset
- 323 Atrial Fibrillation in ST-Segment Elevation Myocardial Infarction Patients After Percutaneous
- 324 Coronary Intervention. Front Cardiovasc Med 9 (2022) 838761.
- [8] L. Xu, M. Wu, S. Chen, Y. Yang, Y. Wang, S. Wu, and Y. Tian, Triglyceride-glucose index 325
- 326 associates with incident heart failure: A cohort study. Diabetes Metab 48 (2022) 101365.
- 327 [9] M.I. Haviroglu, T. Cinar, V. Cicek, A. Palice, G. Avhan, and A.I. Tekkesin, The Triglyceride-
- 328 Glucose Index Can Predict Long-Term Major Adverse Cardiovascular Events in Turkish Patients
- 329 With High Cardiovascular Risk. J Lipid Atheroscler 11 (2022) 280-287.
- 330 [10] B. Yu, Y. Mo, X. Hu, W. Wang, J. Liu, J. Jin, Z. Lun, C.R. Luo Bu, H. Dong, and Y. Zhou,
- 331 Triglyceride-glucose index is associated with quantitative flow ratio in patients with acute ST-
- 332 elevation myocardial infarction after percutaneous coronary intervention. Front Cardiovasc Med 9
- 333 (2022) 1002030.
- 334 [11] E. Luo, D. Wang, G. Yan, Y. Qiao, B. Liu, J. Hou, and C. Tang, High triglyceride-glucose index
- 335 is associated with poor prognosis in patients with acute ST-elevation myocardial infarction after
- 336 percutaneous coronary intervention. Cardiovasc Diabetol 18 (2019) 150.
- 337 [12] O. Sajdeya, A. Beran, M. Mhanna, A. Alharbi, C. Burmeister, Z. Abuhelwa, S.E. Malhas, Y.
- 338 Khader, W. Sayeh, R. Assaly, and G.V. Moukarbel, Triglyceride Glucose Index for the Prediction of
- 339 Subclinical Atherosclerosis and Arterial Stiffness: A Meta-analysis of 37,780 Individuals. Curr Probl
- 340 Cardiol 47 (2022) 101390.
- 341 [13] F.O. Karadeniz, E.A. Sancaktepe, and Y. Karadeniz, High Triglyceride-Glucose Index is
- 342 Associated With Poor Prognosis in Patients With Acute Coronary Syndrome in Long-Term Follow-
- 343 Up. Angiology (2022) 33197221124763.
- 344 [14] R. Huang, Z. Wang, J. Chen, X. Bao, N. Xu, S. Guo, R. Gu, W. Wang, Z. Wei, and L. Wang,
- 345 Prognostic value of triglyceride glucose (TyG) index in patients with acute decompensated heart
- 346 failure. Cardiovasc Diabetol 21 (2022) 88.
- 347 [15] R. Yokoyama, Y. Kanzaki, T. Watanabe, K. Yamamura, T. Komori, Y. Takeda, O. Nakajima,
- 348 K. Sohmiya, and M. Hoshiga, Prevalence and Risk Factors of Silent Cerebral Microbleeds in Patients
- 349 with Coronary Artery Disease. J Stroke Cerebrovasc Dis 31 (2022) 106211.

- Baseline TyG predicts PH
- 350 [16] M. Sun, H. Guo, Y. Wang, and D. Ma, Association of triglyceride glucose index with all-cause
- 351 and cause-specific mortality among middle age and elderly US population. BMC Geriatr 22 (2022)
- 352 461.
- 353 [17] J. Vahatalo, L. Holmstrom, L. Pakanen, K. Kaikkonen, J. Perkiomaki, H. Huikuri, and J.
- 354 Junttila, Coronary Artery Disease as the Cause of Sudden Cardiac Death Among Victims < 50 Years
- 355 of Age. Am J Cardiol 147 (2021) 33-38.
- 356 [18] S. Chen, Y. Dong, M.G. Kiuchi, J. Wang, R. Li, Z. Ling, T. Zhou, Z. Wang, M. Martinek, H.
- 357 Purerfellner, S. Liu, and M.W. Krucoff, Coronary Artery Complication in Kawasaki Disease and the
- 358 Importance of Early Intervention: A Systematic Review and Meta-analysis. JAMA Pediatr 170
- 359 (2016) 1156-1163.
- 360 [19] L. Huang, L. Pang, Q. Gu, T. Yang, W. Li, R. Quan, W. Su, W. Wu, F. Tang, X. Zhu, J. Shen, J.
- 361 Sun, G. Shan, C. Xiong, S. Huang, and J. He, Prevalence, risk factors, and survival associated with
- 362 pulmonary hypertension and heart failure among patients with underlying coronary artery disease: a
- 363 national prospective, multicenter registry study in China. Chin Med J (Engl) 135 (2022) 1837-1845.
- 364 [20] M. Asker, S. Asker, U. Kucuk, H.O. Kucuk, and B. Ozbay, Relationship between coronary
- 365 artery disease and pulmonary arterial pressure in patients with chronic obstructive pulmonary disease.
- 366 Int J Clin Exp Med 7 (2014) 5837-41.
- 367 [21] S.E. Orfanos, and G. Giannakoulas, Pulmonary Hypertension: Current Diagnosis, Approach and
- 368 Treatment at the Dawn of the New European Guidelines. J Clin Med 11 (2022).
- 369 [22] M. Humbert, G. Kovacs, M.M. Hoeper, R. Badagliacca, R.M.F. Berger, M. Brida, J. Carlsen,
- 370 A.J.S. Coats, P. Escribano-Subias, P. Ferrari, D.S. Ferreira, H.A. Ghofrani, G. Giannakoulas, D.G.
- 371 Kiely, E. Mayer, G. Meszaros, B. Nagavci, K.M. Olsson, J. Pepke-Zaba, J.K. Quint, G. Radegran, G.
- 372 Simonneau, O. Sitbon, T. Tonia, M. Toshner, J.L. Vachiery, A. Vonk Noordegraaf, M. Delcroix, S.
- 373 Rosenkranz, and E.E.S.D. Group, 2022 ESC/ERS Guidelines for the diagnosis and treatment of
- 374 pulmonary hypertension. Eur Respir J (2022).
- 375 [23] A. Boucly, J. Weatherald, L. Savale, X. Jais, V. Cottin, G. Prevot, F. Picard, P. de Groote, M.
- 376 Jevnikar, E. Bergot, A. Chaouat, C. Chabanne, A. Bourdin, F. Parent, D. Montani, G. Simonneau, M.
- 377 Humbert, and O. Sitbon, Risk assessment, prognosis and guideline implementation in pulmonary
- 378 arterial hypertension. Eur Respir J 50 (2017).
- 379 [24] Y. Yuan, Y. Zhang, X. Zhang, Y. Yu, B. Li, P. Wang, H. Li, Y. Zhao, C. Shen, and Z. Wang,
- 380 Deciphering the genetic and modular connections between coronary heart disease, idiopathic
- 381 pulmonary arterial hypertension and pulmonary heart disease. Mol Med Rep 14 (2016) 661-70.
- 382 [25] M. Ogiso, N. Serizawa, K. Kamishima, J. Yamaguchi, and N. Hagiwara, Percutaneous coronary
- 383 intervention for left main compression syndrome due to severe idiopathic pulmonary arterial
- 384 hypertension: one year follow-up using intravascular imaging. Intern Med 54 (2015) 801-4.
- 385 [26] I.N. Mansour, R.M. Lang, W.M. Aburuwaida, N.M. Bhave, and R.P. Ward, Evaluation of the
- 386 clinical application of the ACCF/ASE appropriateness criteria for stress echocardiography. J Am Soc
- 387 Echocardiogr 23 (2010) 1199-204.

- **Baseline TyG predicts PH**
- 388 [27] T. Gaisl, C. Schlatzer, E.I. Schwarz, M. Possner, J. Stehli, N.A. Sievi, C.F. Clarenbach, D. Dey,
- P.J. Slomka, P.A. Kaufmann, and M. Kohler, Coronary artery calcification, epicardial fat burden, and
- cardiovascular events in chronic obstructive pulmonary disease. PLoS One 10 (2015) e0126613.
- 391 [28] N. Hirani, N.W. Brunner, A. Kapasi, G. Chandy, L. Rudski, I. Paterson, D. Langleben, S.
- 392 Mehta, L. Mielniczuk, and C.C.P.H. Committee, Canadian Cardiovascular Society/Canadian
- 393 Thoracic Society Position Statement on Pulmonary Hypertension. Can J Cardiol 36 (2020) 977-992.
- 394 [29] Z. Dai, G. Lai, Z. Chen, Y. Li, X. Chen, and G. Lyu, Double Doppler Tei index combined with
- lung ultrasound to evaluate the right ventricular function and lung condition in neonates with
- 396 pulmonary hypertension. J Clin Ultrasound (2022).
- 397 [30] K. Sree Raman, R. Shah, M. Stokes, A. Walls, R.J. Woodman, R. Ananthakrishna, J.G. Walker,
- 398 S. Proudman, P.M. Steele, C.G. De Pasquale, D.S. Celermajer, and J.B. Selvanayagam, Left
- 399 ventricular ischemia in pre-capillary pulmonary hypertension: a cardiovascular magnetic resonance
- 400 study. Cardiovasc Diagn Ther 10 (2020) 1280-1292.
- 401 [31] E. Boxhammer, V. Paar, P. Jirak, C. Koller, O. Demirel, S. Eder, C. Reiter, J. Kammler, J.
- Kellermair, M. Hammerer, H. Blessberger, C. Steinwender, U.C. Hoppe, and M. Lichtenauer, Main
- 403 pulmonary artery diameter in combination with cardiovascular biomarkers. New possibilities to
- identify pulmonary hypertension in patients with severe aortic valve stenosis? Minerva Med (2022).
- 405 [32] P.W. Wilson, Diabetes mellitus and coronary heart disease. Am J Kidney Dis 32 (1998) S89-
- 406 100.
- 407 [33] Y. Zhou, Y. Pan, H. Yan, Y. Wang, Z. Li, X. Zhao, H. Li, X. Meng, C. Wang, L. Liu, and Y.
- Wang, Triglyceride Glucose Index and Prognosis of Patients With Ischemic Stroke. Front Neurol 11
- 409 (2020) 456.
- 410 [34] S. Han, C. Wang, F. Tong, Y. Li, Z. Li, Z. Sun, and Z. Sun, Triglyceride glucose index and its
- 411 combination with the Get with the Guidelines-Heart Failure score in predicting the prognosis in
- patients with heart failure. Front Nutr 9 (2022) 950338.
- 413 [35] Z. Teng, J. Feng, Y. Dong, J. Xu, X. Jiang, H. Chen, Q. Qi, R. Li, W. Chen, and P. Lv,
- 414 Triglyceride glucose index is associated with cerebral small vessel disease burden and cognitive
- impairment in elderly patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne) 13 (2022)
- 416 970122.
- 417 [36] S. Ozbicer, G. Yuksel, and O. Deniz Urgun, Triglyceride glucose index is independently
- 418 associated with a ortic intima-media thickness in patients without known atherosclerotic
- 419 cardiovascular disease or diabetes. Diab Vasc Dis Res 19 (2022) 14791641221136203.
- 420 [37] N. Emlek, and C. Aydin, The relationship between nondipper hypertension and triglyceride
- 421 glucose index. Blood Press Monit (2022).
- 422 [38] R. Zheng, and Y. Mao, Triglyceride and glucose (TyG) index as a predictor of incident
- 423 hypertension: a 9-year longitudinal population-based study. Lipids Health Dis 16 (2017) 175.
- 424 [39] I. Lambrinoudaki, M.V. Kazani, E. Armeni, G. Georgiopoulos, K. Tampakis, D. Rizos, A.
- 425 Augoulea, G. Kaparos, A. Alexandrou, and K. Stamatelopoulos, The TyG Index as a Marker of

- 426 Subclinical Atherosclerosis and Arterial Stiffness in Lean and Overweight Postmenopausal Women.
- 427 Heart Lung Circ 27 (2018) 716-724.
- 428 [40] P. Genereux, Pulmonary Hypertension and Aortic Stenosis: A Piece of the Puzzle. J Am Coll
- 429 Cardiol 80 (2022) 1614-1616.
- 430 [41] S. Xiong, Q. Chen, Z. Zhang, Y. Chen, J. Hou, C. Cui, L. Cheng, H. Su, Y. Long, S. Yang, L.
- 431 Qi, X. Chen, H. Liu, and L. Cai, A synergistic effect of the triglyceride-glucose index and the
- residual SYNTAX score on the prediction of intermediate-term major adverse cardiac events in
- patients with type 2 diabetes mellitus undergoing percutaneous coronary intervention. Cardiovasc
- 434 Diabetol 21 (2022) 115.
- 435 [42] F. Ozkalayci, A. Karagoz, C.Y. Karabay, I.H. Tanboga, E. Turkyilmaz, M. Saygi, and V.
- Oduncu, Prognostic value of triglyceride/glucose index in patients with ST-segment elevation
- 437 myocardial infarction. Biomark Med 16 (2022) 613-622.
- 438 [43] N. Hijioka, M. Kamioka, Y. Matsumoto, M. Nodera, S. Yamada, T. Kaneshiro, A. Yoshihisa, T.
- 439 Ishida, and Y. Takeishi, Clinical impact of insulin resistance on pulmonary vein isolation outcome in
- patients with paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 30 (2019) 479-486.
- [44] R.T. Zamanian, G. Hansmann, S. Snook, D. Lilienfeld, K.M. Rappaport, G.M. Reaven, M.
- Rabinovitch, and R.L. Doyle, Insulin resistance in pulmonary arterial hypertension. Eur Respir J 33
- 443 (2009) 318-24.
- 444 [45] N. Naderi, P. Boobejame, H. Bakhshandeh, A. Amin, S. Taghavi, and M. Maleki, Insulin
- resistance in pulmonary arterial hypertension, is it a novel disease modifier? Res Cardiovasc Med 3
- 446 (2014) e19710.
- 447 [46] X. Xu, R. Huang, Y. Lin, Y. Guo, Z. Xiong, X. Zhong, X. Ye, M. Li, X. Zhuang, and X. Liao,
- 448 High triglyceride-glucose index in young adulthood is associated with incident cardiovascular
- disease and mortality in later life: insight from the CARDIA study. Cardiovasc Diabetol 21 (2022)
- 450 155.

452 453 11. Abbreviations 454 AF: arial fibrillation; 455 ACEI: angiotensin converting enzyme inhibitor; 456 ARB: angiotensin receptor blocker; 457 BNP: B-type natriuretic peptide; 458 BUN: urea nitrogen concentration; 459 CAD: coronary artery disease. 460 CAG: coronary angiography; 461 Ca2+: serum calcium concentration; 462 CCB: calcium channel blockers; 463 CI: Confidence interval; 464 CK-MB: Creatine kinase-MB; 465 Cl<sup>-</sup>: chloride ion; 466 Cr: concentration of plasma creatinine; 467 DBP: diastolic blood pressure; 468 FBG: fasting blood glucose; 469 FS: fractional shortening 470 HDL-C: high-density lipoprotein cholesterol; 471 HR: heart rate; 472 IR: insulin resistance; 473 K+: serum potassium concentration; 474 LAD: end-diastolic internal diameter of the left atria; 475 LDL-C: low-density lipoprotein cholesterol; 476 LVDD: end-diastolic internal diameter of left ventricle;

LVEF: ejection fraction of left ventricle

478 LVPW: left ventricular posterior wall 479 MACE: major adverse cardiovascular events; 480 MACCE: major adverse cardiac and cerebrovascular events; 481 MYO: myoglobin; 482 Na+: sodium concentration; 483 OR: odds ratio; 484 P: phosphate conceentration; 485 PAP: pulmonary arterial pressure; 486 PH: pulmonary hypertension; 487 PCI: percutaneous coronary intervention; 488 RAD: end-diastolic internal diameter of right atria; 489 RVD: end-diastolic internal diameter of right ventricle; 490 SBP: systolic blood pressure; 491 STEMI: ST elevation myocardial infarction; 492 T2DM: diabetes mellitus type 2; 493 TG: triglyceride; 494 TNI: Troponin; 495 TR: tricuspid regurgitation 496 TRA: TR area 497 TRV: TR velocity 498 TyG index: triglyceride-glucose index; 499 500 501 502 503 504

- 505 1. Rojas-Humpire R, Olarte-Durand M, Medina-Ramirez S, Gutierrez-Ajalcrina R, Canaza JF, 506 Huancahuire-Vega S. Insulin Resistance Indexes as Biomarkers of Lifetime Cardiovascular 507 Risk among Adults from Peru. J Nutr Metab 2021;2021:6633700.
- 508 Hill MA, Yang Y, Zhang L et al. Insulin resistance, cardiovascular stiffening and 2. 509 cardiovascular disease. Metabolism 2021;119:154766.
- 510 Li H, Zuo Y, Qian F et al. Triglyceride-glucose index variability and incident cardiovascular 3. 511 disease: a prospective cohort study. Cardiovasc Diabetol 2022;21:105.
- 512 4. Zhao Q, Zhang TY, Cheng YJ et al. Triglyceride-Glucose Index as a Surrogate Marker of 513 Insulin Resistance for Predicting Cardiovascular Outcomes in Nondiabetic Patients with Non-514 ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary 515 Intervention. J Atheroscler Thromb 2021;28:1175-1194.
- 516 5. Araujo SP, Juvanhol LL, Bressan J, Hermsdorff HHM. Triglyceride glucose index: A new 517 biomarker in predicting cardiovascular risk. Prev Med Rep 2022;29:101941.
- 518 6. Zeng X, Han D, Zhou H et al. Triglyceride-Glucose Index and Homeostasis Model 519 Assessment-Insulin Resistance in Young Adulthood and Risk of Incident Congestive Heart 520 Failure in Midlife: The Coronary Artery Risk Development in Young Adults Study. Front 521 Cardiovasc Med 2022;9:944258.
- 522 7. Ling Y, Fu C, Fan Q, Liu J, Jiang L, Tang S. Triglyceride-Glucose Index and New-Onset 523 Atrial Fibrillation in ST-Segment Elevation Myocardial Infarction Patients After 524 Percutaneous Coronary Intervention. Front Cardiovasc Med 2022;9:838761.
- 525 Xu L, Wu M, Chen S et al. Triglyceride-glucose index associates with incident heart failure: 8. 526 A cohort study. Diabetes Metab 2022;48:101365.
- 527 9. Hayiroglu MI, Cinar T, Cicek V, Palice A, Ayhan G, Tekkesin AI. The Triglyceride-Glucose 528 Index Can Predict Long-Term Major Adverse Cardiovascular Events in Turkish Patients With 529 High Cardiovascular Risk. J Lipid Atheroscler 2022;11:280-287.
- 530 10. Yu B, Mo Y, Hu X et al. Triglyceride-glucose index is associated with quantitative flow ratio 531 in patients with acute ST-elevation myocardial infarction after percutaneous coronary 532 intervention. Front Cardiovasc Med 2022;9:1002030.
- 533 11. Luo E, Wang D, Yan G et al. High triglyceride-glucose index is associated with poor 534 prognosis in patients with acute ST-elevation myocardial infarction after percutaneous 535 coronary intervention. Cardiovasc Diabetol 2019;18:150.
- 536 12. Sajdeya O, Beran A, Mhanna M et al. Triglyceride Glucose Index for the Prediction of 537 Subclinical Atherosclerosis and Arterial Stiffness: A Meta-analysis of 37,780 Individuals. 538 Curr Probl Cardiol 2022;47:101390.
- 539 13. Karadeniz FO, Sancaktepe EA, Karadeniz Y. High Triglyceride-Glucose Index is Associated 540 With Poor Prognosis in Patients With Acute Coronary Syndrome in Long-Term Follow-Up. 541 Angiology 2022:33197221124763.
- 542 14. Huang R, Wang Z, Chen J et al. Prognostic value of triglyceride glucose (TyG) index in 543 patients with acute decompensated heart failure. Cardiovasc Diabetol 2022;21:88.
- 544 15. Yokoyama R, Kanzaki Y, Watanabe T et al. Prevalence and Risk Factors of Silent Cerebral 545 Microbleeds in Patients with Coronary Artery Disease. J Stroke Cerebrovasc Dis 546 2022;31:106211.

- 547 16. Sun M, Guo H, Wang Y, Ma D. Association of triglyceride glucose index with all-cause and cause-specific mortality among middle age and elderly US population. BMC Geriatr 548 549 2022;22:461.
- 550 17. Vahatalo J, Holmstrom L, Pakanen L et al. Coronary Artery Disease as the Cause of Sudden 551 Cardiac Death Among Victims < 50 Years of Age. Am J Cardiol 2021;147:33-38.
- 552 Chen S, Dong Y, Kiuchi MG et al. Coronary Artery Complication in Kawasaki Disease and 18. 553 the Importance of Early Intervention: A Systematic Review and Meta-analysis. JAMA 554 Pediatr 2016;170:1156-1163.
- 555 19. Huang L, Pang L, Gu Q et al. Prevalence, risk factors, and survival associated with 556 pulmonary hypertension and heart failure among patients with underlying coronary artery 557 disease: a national prospective, multicenter registry study in China. Chin Med J (Engl) 558 2022;135:1837-1845.
- 559 20. Asker M, Asker S, Kucuk U, Kucuk HO, Ozbay B. Relationship between coronary artery 560 disease and pulmonary arterial pressure in patients with chronic obstructive pulmonary 561 disease. Int J Clin Exp Med 2014;7:5837-41.
- 562 21. Orfanos SE, Giannakoulas G. Pulmonary Hypertension: Current Diagnosis, Approach and 563 Treatment at the Dawn of the New European Guidelines. J Clin Med 2022;11.
- Humbert M, Kovacs G, Hoeper MM et al. 2022 ESC/ERS Guidelines for the diagnosis and 564 22. 565 treatment of pulmonary hypertension. Eur Respir J 2022.
- 566 23. Boucly A, Weatherald J, Savale L et al. Risk assessment, prognosis and guideline 567 implementation in pulmonary arterial hypertension. Eur Respir J 2017;50.
- 568 24. Yuan Y, Zhang Y, Zhang X et al. Deciphering the genetic and modular connections between 569 coronary heart disease, idiopathic pulmonary arterial hypertension and pulmonary heart 570 disease. Mol Med Rep 2016;14:661-70.
- 571 25. Ogiso M, Serizawa N, Kamishima K, Yamaguchi J, Hagiwara N. Percutaneous coronary 572 intervention for left main compression syndrome due to severe idiopathic pulmonary arterial 573 hypertension: one year follow-up using intravascular imaging. Intern Med 2015;54:801-4.
- 574 26. Mansour IN, Lang RM, Aburuwaida WM, Bhave NM, Ward RP. Evaluation of the clinical 575 application of the ACCF/ASE appropriateness criteria for stress echocardiography. J Am Soc 576 Echocardiogr 2010;23:1199-204.
- 577 27. Gaisl T, Schlatzer C, Schwarz EI et al. Coronary artery calcification, epicardial fat burden, 578 and cardiovascular events in chronic obstructive pulmonary disease. PLoS One 579 2015;10:e0126613.
- 580 28. Hirani N, Brunner NW, Kapasi A et al. Canadian Cardiovascular Society/Canadian Thoracic 581 Society Position Statement on Pulmonary Hypertension. Can J Cardiol 2020;36:977-992.
- 582 29. Dai Z, Lai G, Chen Z, Li Y, Chen X, Lyu G. Double Doppler Tei index combined with lung 583 ultrasound to evaluate the right ventricular function and lung condition in neonates with 584 pulmonary hypertension. J Clin Ultrasound 2022.
- 585 Sree Raman K, Shah R, Stokes M et al. Left ventricular ischemia in pre-capillary pulmonary 30. 586 hypertension: a cardiovascular magnetic resonance study. Cardiovasc Diagn Ther 587 2020;10:1280-1292.

- 588 31. Boxhammer E, Paar V, Jirak P et al. Main pulmonary artery diameter in combination with cardiovascular biomarkers. New possibilities to identify pulmonary hypertension in patients 589 590 with severe aortic valve stenosis? Minerva Med 2022.
- 591 32. Wilson PW. Diabetes mellitus and coronary heart disease. Am J Kidney Dis 1998;32:S89-592 100.
- 593 33. Zhou Y, Pan Y, Yan H et al. Triglyceride Glucose Index and Prognosis of Patients With 594 Ischemic Stroke. Front Neurol 2020;11:456.
- 595 Han S, Wang C, Tong F et al. Triglyceride glucose index and its combination with the Get 34. 596 with the Guidelines-Heart Failure score in predicting the prognosis in patients with heart 597 failure. Front Nutr 2022;9:950338.
- 598 35. Teng Z, Feng J, Dong Y et al. Triglyceride glucose index is associated with cerebral small 599 vessel disease burden and cognitive impairment in elderly patients with type 2 diabetes 600 mellitus. Front Endocrinol (Lausanne) 2022;13:970122.
- 601 36. Ozbicer S, Yuksel G, Deniz Urgun O. Triglyceride glucose index is independently associated 602 with aortic intima-media thickness in patients without known atherosclerotic cardiovascular disease or diabetes. Diab Vasc Dis Res 2022;19:14791641221136203. 603
- 604 37. Emlek N, Aydin C. The relationship between nondipper hypertension and triglyceride glucose 605 index. Blood Press Monit 2022.
- 606 38. Zheng R, Mao Y. Triglyceride and glucose (TyG) index as a predictor of incident 607 hypertension: a 9-year longitudinal population-based study. Lipids Health Dis 2017;16:175.
- 608 39. Lambrinoudaki I, Kazani MV, Armeni E et al. The TyG Index as a Marker of Subclinical 609 Atherosclerosis and Arterial Stiffness in Lean and Overweight Postmenopausal Women. Heart Lung Circ 2018;27:716-724. 610
- 611 40. Genereux P. Pulmonary Hypertension and Aortic Stenosis: A Piece of the Puzzle. J Am Coll 612 Cardiol 2022;80:1614-1616.
- 613 41. Xiong S, Chen O, Zhang Z et al. A synergistic effect of the triglyceride-glucose index and the 614 residual SYNTAX score on the prediction of intermediate-term major adverse cardiac events in patients with type 2 diabetes mellitus undergoing percutaneous coronary intervention. 615 616 Cardiovasc Diabetol 2022;21:115.
- 617 42. Ozkalayci F, Karagoz A, Karabay CY et al. Prognostic value of triglyceride/glucose index in 618 patients with ST-segment elevation myocardial infarction. Biomark Med 2022;16:613-622.
- 619 43. Hijioka N, Kamioka M, Matsumoto Y et al. Clinical impact of insulin resistance on 620 pulmonary vein isolation outcome in patients with paroxysmal atrial fibrillation. J Cardiovasc 621 Electrophysiol 2019;30:479-486.
- 622 44. Zamanian RT, Hansmann G, Snook S et al. Insulin resistance in pulmonary arterial hypertension. Eur Respir J 2009;33:318-24. 623
- 624 45. Naderi N, Boobejame P, Bakhshandeh H, Amin A, Taghavi S, Maleki M. Insulin resistance in 625 pulmonary arterial hypertension, is it a novel disease modifier? Res Cardiovasc Med 626 2014;3:e19710.
- Xu X, Huang R, Lin Y et al. High triglyceride-glucose index in young adulthood is associated 627 46. 628 with incident cardiovascular disease and mortality in later life: insight from the CARDIA 629 study. Cardiovasc Diabetol 2022;21:155.

630

## **Tables**

1

2

### Table 1 The characteristics of the patients

•	Overall (n = 247)	Non-PH (n = 225)	PH (n = 22)	p value
Age (years)	68.84±12.12	68.54±12.16	71.91±11.51	0.214
BMI (kg/m <sup>2</sup> )	24.10±3.42	24.18±3.49	$23.22 \pm$	0.206
Gender, female, n (%)	92(37.2%)	85(37.8%)	7(31.8%)	0.581
Smoking, n (%)	104(42.1%)	97(43.1%)	7(31.8%)	0.306
Drinking n (%)	43(17.4%)	40(17.8%)	3(13.6%)	0.775
Cerebral infarction history n (%)	55(22.3%)	46(20.4%)	9(40.9%)	0.028
Hypertension n (%) T2DM, n (%) Meditation	158(64%)	144(64.0%)	14(63.6%)	0.490
	70(28.3%)	64(28.4%)	6(27.3%)	0.927
CCB, n (%)	50(20.2%)	45(20.0%)	5(22.7%)	0.573
ACEI/ARB, n (%)	175(70.9%)	161(71.6%)	16(72.7%)	0.475
β-blocker, n (%) Diuretic, n (%)	175(70.9%)	161(71.6%)	14(63.6%)	0.884
	55(22.3%)	50(22.2%)	5(22.7%)	0.784

The Cerebral infarction history showed significant difference between PH and non-PH groups. ACEI: angiotension converting enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: calcium channel blockers;T2DM: diabetes mellitus type 2.

Table 2 Hemodynamics changes from baseline to follow-up

9 10

•	Baseline	Follow up	р
LAD (mm)	35.69±5.00	35.74±4.59	< 0.001
LVDD (mm)	47.02±6.02	$47.73\pm6.08$	< 0.001
LVEF (%)	61.12±9.91	61.03±8.68	< 0.001
SV (ml)	70.32±18.59	$70.35 \pm 20.06$	0.241
RAD (mm)	35.45±4.28	35.38±3.64	< 0.001
RVD (mm)	34.02±3.21	33.79±3.82	< 0.001
TRA (cm <sup>2</sup> )	0.00(0.00-1.00)	0.50(0.00-1.00)	0.127
TRV (m/s)	0.00(0.00-243.00	200.00(0.00-240.00)	0.573

The parameters of hemodynamics changed significantly from baseline to the follow-up.

Table 3 Differences between PH and non-PH patients

Echocardiographic parameters	ole 3 Differences between PH an	Non-PH patients $(n = 225)$	PH patients (n = 22)	P value	
LVDD (mm)	hocardiographic parameters	(4 ==0)	()		
LVEF (%)         61.29±9.57         59.41±13.084           SV (ml)         70.04±18.57         73.13±18.91           RAD (mm)         35.33±2.00         36.68±5.04           RVD (mm)         33.95±3.15         34.81±3.78           FS (%)         33.72±7.69         32.23±8.61           TRA (cm²)         0.00(0.00-1.00)         0.500(0.00-1.52)           TRV (m/s)         0.00(0.00-243.38)         100.00(0.00-245.00)           Biomarkers         BNP (pg/ml)         68.00 (18.05-196.00)         174.00 (76.25-447.75)           MYO (ng/ml)         56.30 (42.65-77.25)         76.30(64.38-126.35)           CK-MB (ng/ml)         1.00(1.00-1.00)         1.00(1.00-1.00)           Electrolytes         Weg²* (mmol/L)         3.98±0.73         3.90±0.47           K² (mmol/L)         3.98±0.73         3.90±0.47           Ca²* (mmol/L)         139.38±4.80         139.34±3.88           1 Cr (mmol/L)         105.68±5.08         104.97±3.96           TCO₂ (mmol/L)         24.70±5.87         25.14±2.44           P (mmol/L)         1.1±0.49         1.08±0.30           Renal function         U/A (µmol/L)         78.20 (67.30-93.85)         79.95 (68.45-93.90)           BUN (µmol/L)         7.12±6.38         7.77±4.57 <td>D (mm)</td> <td>35.52±4.97</td> <td>37.36±5.09</td> <td>0.100</td>	D (mm)	35.52±4.97	37.36±5.09	0.100	
SV (ml)	DD (mm)	46.89±5.71	48.31±8.64	0.290	
RAD (mm) 35.33±2.00 36.68±5.04  RVD (mm) 33.95±3.15 34.81±3.78  FS (%) 33.72±7.69 32.23±8.61  TRA (cm²) 0.00(0.00-1.00) 0.500(0.00-1.52)  TRV (m/s) 0.00(0.00-243.38) 100.00(0.00-245.00)  Biomarkers  BNP (pg/ml) 68.00 (18.05-196.00) 174.00 (76.25-447.75)  TNI (ng/ml) 0.05(0.05-0.05) 0.05(0.05-0.05)  MYO (ng/ml) 56.30 (42.65-77.25) 76.30(64.38-126.35)  CK-MB (ng/ml) 1.00(1.00-1.00) 1.00(1.00-1.00)  Electrolytes  Mg²² (mmol/L) 0.966±0.132 0.95±0.116  K² (mmol/L) 3.98±0.73 3.90±0.47  Ca²⁴ (mmol/L) 139.38±4.80 139.34±3.88  CI (mmol/L) 105.68±5.08 104.97±3.96  TCO <sub>2</sub> (mmol/L) 1.11±0.49 1.08±0.30  Renal function  UA(μmol/L) 369.70 (304.55-442.30) 355.05 (282.30-444.47)  Cr (μmol/L) 78.30 (67.30-93.85) 79.95 (68.45-93.90)  BUN (μmol/L) 1.26 (0.92-1.80) 1.49 (0.35-2.42)  BUN (μmol/L) 1.25 (0.92-1.80) 1.49 (0.35-2.42)  HDL-C (mmol/L) 1.26 (0.87-0.16) 0.915 (0.770-1.071)  TGDL-C (mmol/L) 1.26 (0.92-1.80) 1.49 (0.35-2.42)  HDL-C (mmol/L) 2.31 (1.74-2.96) 2.215 (1.780-2.59)  Glu (mmol/L) 4.74 (4.20-5.52) 5.32 (4.32-6.48)  TyG index 6.95 (6.47-7.36) 7.15 (6.49-7.96)  Basic parameters  HR (mmHg) 72.54±14.50 76.20±2.01	EF (%)	61.29±9.57	59.41±13.084	0.396	
RVD (mm)         33.95±3.15         34.81±3.78           FS (%)         33.72±7.69         32.23±8.61           TRA (cm²)         0.00(0.00-1.00)         0.500(0.00-1.52)           TRV (m/s)         0.00(0.00-243.38)         100.00(0.00-245.00)           Biomarkers         BNP (pg/ml)         68.00 (18.05-196.00)         174.00 (76.25-447.75)           TNI (ng/ml)         0.05(0.05-0.05)         0.05(0.05-0.05)           MYO (ng/ml)         56.30 (42.65-77.25)         76.30(64.38-126.35)           CK-MB (ng/ml)         1.00(1.00-1.00)         1.00(1.00-1.00)           Electrolytes         Mg² (mmol/L)         3.98±0.73         3.90±0.47           K² (mmol/L)         3.98±0.73         3.90±0.47         3.90±0.47           Ca²- (mmol/L)         2.200 (2.12-2.30)         2.18 (2.11-2.26)         139.34±3.88         104.97±3.96           Cl (mmol/L)         139.38±4.80         139.34±3.88         104.97±3.96         170.00         100	(ml)	70.04±18.57	73.13±18.91	0.457	
FS (%) 33.72±7.69 32.23±8.61  TRA (cm²) 0.00(0.00-1.00) 0.500(0.00-1.52)  TRV (m/s) 0.00(0.00-243.38) 100.00(0.00-245.00)  Biomarkers  BNP (pg/ml) 68.00 (18.05-196.00) 174.00 (76.25-447.75)  TNI (ng/ml) 0.05(0.05-0.05) 0.05(0.05-0.05)  MYO (ng/ml) 56.30 (42.65-77.25) 76.30(64.38-126.35)  CK-MB (ng/ml) 1.00(1.00-1.00) 1.00(1.00-1.00)  Electrolytes  Mg²⁻ (mmol/L) 0.966±0.132 0.95±0.116  K⁻ (mmol/L) 3.98±0.73 3.90±0.47  Ca²⁺ (mmol/L) 139.38±4.80 139.34±3.88  Cl (mmol/L) 139.38±4.80 139.34±3.88  Cl (mmol/L) 105.68±5.08 104.97±3.96  TCO₂ (mmol/L) 24.70±5.87 25.14±2.44  P (mmol/L) 1.11±0.49 1.08±0.30  Renal function  UA(μmol/L) 369.70 (304.55-442.30) 355.05 (282.30-444.47)  Cr (μmol/L) 78.30 (67.30-93.85) 79.95 (68.45-93.90)  BUN (μmol/L) 7.12±6.38 7.77±4.57  eGFR(mL/min/1.73m²) 81.12 (61.10-92.44) 78.88 (60.25-85.46)  Serum lipids and glucose  TC (mmol/L) 1.25 (0.92-1.80) 1.49 (0.35-2.42)  HDL-C (mmol/L) 1.06 (0.870-1.26) 0.915 (0.770-1.071)  LDL-C (mmol/L) 1.06 (0.870-1.26) 0.915 (0.770-1.071)  LDL-C (mmol/L) 4.74 (4.20-5.52) 5.32 (4.32-6.48)  TyG index 6.95(6.47-7.36) 7.15(6.49-7.96)  Basic parameters  HR (mmHg) 72.54±14.50 76.20±2.01	AD (mm)	35.33±2.00	$36.68 \pm 5.04$	0.158	
TRA (cm²) 0.00(0.00-1.00) 0.500(0.00-1.52) TRV (m/s) 0.00(0.00-243.38) 100.00(0.00-245.00)  Biomarkers  BNP (pg/ml) 68.00 (18.05-196.00) 174.00 (76.25-447.75) TNI (ng/ml) 0.05(0.05-0.05) 0.05(0.05-0.05) MYO (ng/ml) 56.30 (42.65-77.25) 76.30(64.38-126.35) CK-MB (ng/ml) 1.00(1.00-1.00) 1.00(1.00-1.00)  Electrolytes  Mg²¹ (mmol/L) 0.966±0.132 0.95±0.116 K¹ (mmol/L) 13.98±0.73 3.90±0.47  Ca²¹ (mmol/L) 139.38±4.80 139.34±3.88 Cl (mmol/L) 139.38±4.80 139.34±3.88 Cl (mmol/L) 105.68±5.08 104.97±3.96 TCO₂ (mmol/L) 1.11±0.49 1.08±0.30  Renal function  UA(μmol/L) 369.70 (304.55-442.30) 355.05 (282.30-444.47) Cr (μmol/L) 78.30 (67.30-93.85) 79.95 (68.45-93.90) BUN (μmol/L) 7.12±6.38 7.77±4.57  eGFR (mL/min/1.73m²) 81.12 (61.10-92.44) 78.88 (60.25-85.46)  Serum lipids and glucose  TC (mmol/L) 1.25 (0.92-1.80) 1.49 (0.35-2.42) HDL-C (mmol/L) 2.31 (1.74-2.96) 2.215 (1.780-2.59) Glu (mmol/L) 4.74 (4.20-5.52) 5.32 (4.32-6.48) TyG index 6.95(6.47-7.36) 71.5(6.49-7.96) HbA1c (%) 6.30(5.90-6.75) 6.48 (6.075-7.00)  Basic parameters  HR (mmHg) 72.54±14.50 76.20±22.01	TD (mm)	33.95±3.15	34.81±3.78	0.226	
TRV (m/s)         0.00(0.00-243.38)         100.00(0.00-245.00)           Biomarkers         BNP (pg/ml)         68.00 (18.05-196.00)         174.00 (76.25-447.75)           TNI (ng/ml)         0.05(0.05-0.05)         0.05(0.05-0.05)           MYO (ng/ml)         56.30 (42.65-77.25)         76.30(64.38-126.35)           CK-MB (ng/ml)         1.00(1.00-1.00)         1.00(1.00-1.00)           Electrolytes         1.00(1.00-1.00)         1.00(1.00-1.00)           Mg²+ (mmol/L)         0.966±0.132         0.95±0.116           K⁻ (mmol/L)         3.98±0.73         3.90±0.47           Ca²+ (mmol/L)         1.39.38±4.80         139.34±3.88           Cl¹ (mmol/L)         105.68±5.08         104.97±3.96           TCO₂ (mmol/L)         24.70±5.87         25.14±2.44           P (mmol/L)         1.08±0.30           Renal function         1.04(µmol/L)         369.70 (304.55-442.30)         355.05 (282.30-444.47)           Cr (µmol/L)         369.70 (304.55-442.30)         355.05 (282.30-444.47)           BUN (µmol/L)         78.30 (67.30-93.85)         79.95 (68.45-93.90)           BUN (µmol/L)         7.12±6.38         7.77±4.57           eGFR(mL/min/1.73m²)         81.12 (61.10-92.44)         78.88 (60.25-85.46)           Serum lipids and glucose	(%)	33.72±7.69	32.23±8.61	0.292	
Biomarkers  BNP (pg/ml) 68.00 (18.05-196.00) 174.00 (76.25-447.75)  TNI (ng/ml) 0.05(0.05-0.05) 0.05(0.05-0.05)  MYO (ng/ml) 56.30 (42.65-77.25) 76.30(64.38-126.35)  CK-MB (ng/ml) 1.00(1.00-1.00) 1.00(1.00-1.00)  Electrolytes  Mg²⁻ (mmol/L) 0.966±0.132 0.95±0.116  K⁻ (mmol/L) 3.98±0.73 3.99±0.47  Ca²⁺ (mmol/L) 139.38±4.80 139.34±3.88  Cl⁻ (mmol/L) 105.68±5.08 104.97±3.96  TCO₂ (mmol/L) 105.68±5.08 104.97±3.96  TCO₂ (mmol/L) 1.11±0.49 1.08±0.30  Renal function  UA(µmol/L) 369.70 (304.55-442.30) 355.05 (282.30-444.47)  Cr (µmol/L) 78.30 (67.30-93.85) 79.95 (68.45-93.90)  BUN (µmol/L) 7.12±6.38 7.77±4.57  eGFR(mL/min/1.73m²) 81.12 (61.10-92.44) 78.88 (60.25-85.46)  Serum lipids and glucose  TC (mmol/L) 1.06 (0.870-1.26) 0.915 (0.770-1.071)  LDL-C (mmol/L) 2.31 (1.74-2.96) 2.215 (1.780-2.59)  Glu (mmol/L) 4.74 (4.20-5.52) 5.32 (4.32-6.48)  TyG index 6.95(6.47-7.36) 7.15(6.49-7.96)  Blace (%) 6.30(5.90-6.75) 6.48 (6.075-7.00)  Basic parameters  HR (mmHg) 72.54±14.50 76.20±22.01	$A (cm^2)$	0.00(0.00-1.00)	0.500(0.00-1.52)	0.512	
BNP (pg/ml)         68.00 (18.05-196.00)         174.00 (76.25-447.75)           TNI (ng/ml)         0.05(0.05-0.05)         0.05(0.05-0.05)           MYO (ng/ml)         56.30 (42.65-77.25)         76.30(64.38-126.35)           CK-MB (ng/ml)         1.00(1.00-1.00)         1.00(1.00-1.00)           Electrolytes         Mg²¹ (mmol/L)         0.966±0.132         0.95±0.116           Mg²¹ (mmol/L)         3.98±0.73         3.90±0.47           Ca²¹ (mmol/L)         139.38±4.80         139.34±3.88           Cl (mmol/L)         105.68±5.08         104.97±3.96           TCO2 (mmol/L)         24.70±5.87         25.14±2.44           P (mmol/L)         1.11±0.49         1.08±0.30           Renal function         Renal function           UA(μmol/L)         369.70 (304.55-442.30)         355.05 (282.30-444.47)           Cr (μmol/L)         78.30 (67.30-93.85)         79.95 (68.45-93.90)           BUN (μmol/L)         7.12±6.38         7.77±4.57           eGFR(mL/min/1.73m²)         81.12 (61.10-92.44)         78.88 (60.25-85.46)           Serum lipids and glucose         TC (mmol/L)         1.25 (0.92-1.80)         1.49 (0.35-2.42)           HDL-C (mmol/L)         1.06 (0.870-1.26)         0.915 (0.770-1.071)         1.DL-C (mmol/L)         2.215 (1.780-2.59)	V (m/s)	0.00(0.00-243.38)	100.00(0.00-245.00)	0.736	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	omarkers				
MYO (ng/ml)         56.30 (42.65-77.25)         76.30(64.38-126.35)           CK-MB (ng/ml)         1.00(1.00-1.00)         1.00(1.00-1.00)           Electrolytes         Bg²+ (mmol/L)         0.966±0.132         0.95±0.116           K† (mmol/L)         3.98±0.73         3.90±0.47           Ca²+ (mmol/L)         2.200 (2.12-2.30)         2.18 (2.11-2.26)           Na†(mmol/L)         139.38±4.80         139.34±3.88           Cl* (mmol/L)         105.68±5.08         104.97±3.96           TCO <sub>2</sub> (mmol/L)         24.70±5.87         25.14±2.44           P (mmol/L)         369.70 (304.55-442.30)         355.05 (282.30-444.47)           Cr (μmol/L)         78.30 (67.30-93.85)         79.95 (68.45-93.90)           BUN (μmol/L)         7.12±6.38         7.77±4.57           eGFR(mL/min/1.73m²)         81.12 (61.10-92.44)         78.88 (60.25-85.46)           Serum lipids and glucose           TC (mmol/L)         3.74(2.96-4.52)         3.72 (2.97-4.19)           TG (mmol/L)         1.25 (0.92-1.80)         1.49 (0.35-2.42)           HDL-C (mmol/L)         2.31 (1.74-2.96)         2.215 (1.780-2.59)           Glu (mmol/L)         4.74 (4.20-5.52)         5.32 (4.32-6.48)           TyG index         6.95 (6.47-7.36)         7.15 (6.49-7.96)	NP (pg/ml)	68.00 (18.05-196.00)	174.00 (76.25-447.75)	0.007	
CK-MB (ng/ml)         1.00(1.00-1.00)         1.00(1.00-1.00)           Electrolytes         Mg²+ (mmol/L)         0.966±0.132         0.95±0.116           K* (mmol/L)         3.98±0.73         3.90±0.47           Ca²+ (mmol/L)         2.200 (2.12-2.30)         2.18 (2.11-2.26)           Na⁺ (mmol/L)         139.38±4.80         139.34±3.88           Cl* (mmol/L)         105.68±5.08         104.97±3.96           TCO₂ (mmol/L)         24.70±5.87         25.14±2.44           P (mmol/L)         1.11±0.49         1.08±0.30           Renal function         UA(μmol/L)         369.70 (304.55-442.30)         355.05 (282.30-444.47)           Cr (μmol/L)         78.30 (67.30-93.85)         79.95 (68.45-93.90)           BUN (μmol/L)         7.12±6.38         7.77±4.57           eGFR(mL/min/1.73m²)         81.12 (61.10-92.44)         78.88 (60.25-85.46)           Serum lipids and glucose         TC (mmol/L)         3.74(2.96-4.52)         3.72 (2.97-4.19)           TG (mmol/L)         1.25 (0.92-1.80)         1.49 (0.35-2.42)           HDL-C (mmol/L)         2.31 (1.74-2.96)         2.215 (1.780-2.59)           Glu (mmol/L)         4.74 (4.20-5.52)         5.32 (4.32-6.48)           TyG index         6.95 (6.47-7.36)         7.15	II (ng/ml)	0.05(0.05-0.05)	0.05(0.05-0.05)	0.307	
Electrolytes           Mg²+ (mmol/L)         0.966±0.132         0.95±0.116           K* (mmol/L)         3.98±0.73         3.90±0.47           Ca²+ (mmol/L)         2.200 (2.12-2.30)         2.18 (2.11-2.26)           Na⁺ (mmol/L)         139.38±4.80         139.34±3.88           Cl* (mmol/L)         105.68±5.08         104.97±3.96           TCO2 (mmol/L)         24.70±5.87         25.14±2.44           P (mmol/L)         1.11±0.49         1.08±0.30           Renal function         369.70 (304.55-442.30)         355.05 (282.30-444.47)           Cr (μmol/L)         78.30 (67.30-93.85)         79.95 (68.45-93.90)           BUN (μmol/L)         7.12±6.38         7.77±4.57           eGFR(mL/min/1.73m²)         81.12 (61.10-92.44)         78.88 (60.25-85.46)           Serum lipids and glucose         77         1.25 (0.92-1.80)         1.49 (0.35-2.42)           HDL-C (mmol/L)         3.74(2.96-4.52)         3.72 (2.97-4.19)           TG (mmol/L)         1.25 (0.92-1.80)         1.49 (0.35-2.42)           HDL-C (mmol/L)         2.31 (1.74-2.96)         2.215 (1.780-2.59)           Glu (mmol/L)         4.74 (4.20-5.52)         5.32 (4.32-6.48)           TyG index         6.95 (6.47-7.36)         7.15 (6.49-7.96)	YO (ng/ml)	56.30 (42.65-77.25)	76.30(64.38-126.35)	< 0.001	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		1.00(1.00-1.00)	1.00(1.00-1.00)	0.808	
$\begin{array}{c} K^+(\text{mmol/L}) & 3.98\pm0.73 & 3.90\pm0.47 \\ Ca^{2+}(\text{mmol/L}) & 2.200  (2.12\text{-}2.30) & 2.18  (2.11\text{-}2.26) \\ Na^+(\text{mmol/L}) & 139.38\pm4.80 & 139.34\pm3.88 \\ Cl^+(\text{mmol/L}) & 105.68\pm5.08 & 104.97\pm3.96 \\ TCO_2  (\text{mmol/L}) & 24.70\pm5.87 & 25.14\pm2.44 \\ P  (\text{mmol/L}) & 1.11\pm0.49 & 1.08\pm0.30 \\ \hline Renal  function & & & & & & & & & & & & & & & & & & &$		0.066+0.132	0.05±0.116	0.700	
Na <sup>+</sup> (mmol/L)       139.38±4.80       139.34±3.88         Cl' (mmol/L)       105.68±5.08       104.97±3.96         TCO <sub>2</sub> (mmol/L)       24.70±5.87       25.14±2.44         P (mmol/L)       1.11±0.49       1.08±0.30         Renal function         UA(μmol/L)       369.70 (304.55-442.30)       355.05 (282.30-444.47)         Cr (μmol/L)       78.30 (67.30-93.85)       79.95 (68.45-93.90)         BUN (μmol/L)       7.12±6.38       7.77±4.57         eGFR(mL/min/1.73m²)       81.12 (61.10-92.44)       78.88 (60.25-85.46)         Serum lipids and glucose         TC (mmol/L)       3.74(2.96-4.52)       3.72 (2.97-4.19)         TG (mmol/L)       1.25 (0.92-1.80)       1.49 (0.35-2.42)         HDL-C (mmol/L)       1.06 (0.870-1.26)       0.915 (0.770-1.071)         LDL-C (mmol/L)       2.31 (1.74-2.96)       2.215 (1.780-2.59)         Glu (mmol/L)       4.74 (4.20-5.52)       5.32 (4.32-6.48)         TyG index       6.95(6.47-7.36)       7.15(6.49-7.96)         HbA1c (%)       6.30(5.90-6.75)       6.48 (6.075-7.00)         Basic parameters         HR (mmHg)       72.54±14.50       76.20±22.01				0.642	
Na <sup>+</sup> (mmol/L)         139.38±4.80         139.34±3.88           Cl' (mmol/L)         105.68±5.08         104.97±3.96           TCO <sub>2</sub> (mmol/L)         24.70±5.87         25.14±2.44           P (mmol/L)         1.11±0.49         1.08±0.30           Renal function           UA(μmol/L)         369.70 (304.55-442.30)         355.05 (282.30-444.47)           Cr (μmol/L)         78.30 (67.30-93.85)         79.95 (68.45-93.90)           BUN (μmol/L)         7.12±6.38         7.77±4.57           eGFR(mL/min/1.73m²)         81.12 (61.10-92.44)         78.88 (60.25-85.46)           Serum lipids and glucose         TC (mmol/L)         3.74(2.96-4.52)         3.72 (2.97-4.19)           TG (mmol/L)         1.25 (0.92-1.80)         1.49 (0.35-2.42)           HDL-C (mmol/L)         1.06 (0.870-1.26)         0.915 (0.770-1.071)           LDL-C (mmol/L)         2.31 (1.74-2.96)         2.215 (1.780-2.59)           Glu (mmol/L)         4.74 (4.20-5.52)         5.32 (4.32-6.48)           TyG index         6.95(6.47-7.36)         7.15(6.49-7.96)           HbA1c (%)         6.30(5.90-6.75)         6.48 (6.075-7.00)           Basic parameters         HR (mmHg)         72.54±14.50         76.20±22.01	2+ (mmol/L)	2 200 (2 12-2 30)	2 18 (2 11-2 26)	0.705	
TCO₂ (mmol/L)         24.70±5.87         25.14±2.44           P (mmol/L)         1.11±0.49         1.08±0.30           Renal function         UA(μmol/L)           UA(μmol/L)         369.70 (304.55-442.30)         355.05 (282.30-444.47)           Cr (μmol/L)         78.30 (67.30-93.85)         79.95 (68.45-93.90)           BUN (μmol/L)         7.12±6.38         7.77±4.57           eGFR(mL/min/1.73m²)         81.12 (61.10-92.44)         78.88 (60.25-85.46)           Serum lipids and glucose         TC (mmol/L)         3.74(2.96-4.52)         3.72 (2.97-4.19)           TG (mmol/L)         1.25 (0.92-1.80)         1.49 (0.35-2.42)           HDL-C (mmol/L)         1.06 (0.870-1.26)         0.915 (0.770-1.071)           LDL-C (mmol/L)         2.31 (1.74-2.96)         2.215 (1.780-2.59)           Glu (mmol/L)         4.74 (4.20-5.52)         5.32 (4.32-6.48)           TyG index         6.95(6.47-7.36)         7.15(6.49-7.96)           HbA1c (%)         6.30(5.90-6.75)         6.48 (6.075-7.00)           Basic parameters         HR (mmHg)         72.54±14.50         76.20±22.01				0.970	
P (mmol/L)       1.11±0.49       1.08±0.30         Renal function       UA(μmol/L)       369.70 (304.55-442.30)       355.05 (282.30-444.47)         Cr (μmol/L)       78.30 (67.30-93.85)       79.95 (68.45-93.90)         BUN (μmol/L)       7.12±6.38       7.77±4.57         eGFR(mL/min/1.73m²)       81.12 (61.10-92.44)       78.88 (60.25-85.46)         Serum lipids and glucose         TC (mmol/L)       3.74(2.96-4.52)       3.72 (2.97-4.19)         TG (mmol/L)       1.25 (0.92-1.80)       1.49 (0.35-2.42)         HDL-C (mmol/L)       1.06 (0.870-1.26)       0.915 (0.770-1.071)         LDL-C (mmol/L)       2.31 (1.74-2.96)       2.215 (1.780-2.59)         Glu (mmol/L)       4.74 (4.20-5.52)       5.32 (4.32-6.48)         TyG index       6.95(6.47-7.36)       7.15(6.49-7.96)         HbA1c (%)       6.30(5.90-6.75)       6.48 (6.075-7.00)         Basic parameters         HR (mmHg)       72.54±14.50       76.20±22.01				0.552	
Renal function         UA(μmol/L)       369.70 (304.55-442.30)       355.05 (282.30-444.47)         Cr (μmol/L)       78.30 (67.30-93.85)       79.95 (68.45-93.90)         BUN (μmol/L)       7.12±6.38       7.77±4.57         eGFR(mL/min/1.73m²)       81.12 (61.10-92.44)       78.88 (60.25-85.46)         Serum lipids and glucose         TC (mmol/L)       3.74(2.96-4.52)       3.72 (2.97-4.19)         TG (mmol/L)       1.25 (0.92-1.80)       1.49 (0.35-2.42)         HDL-C (mmol/L)       1.06 (0.870-1.26)       0.915 (0.770-1.071)         LDL-C (mmol/L)       2.31 (1.74-2.96)       2.215 (1.780-2.59)         Glu (mmol/L)       4.74 (4.20-5.52)       5.32 (4.32-6.48)         TyG index       6.95(6.47-7.36)       7.15(6.49-7.96)         HbA1c (%)       6.30(5.90-6.75)       6.48 (6.075-7.00)         Basic parameters         HR (mmHg)       72.54±14.50       76.20±22.01			_	0.732	
UA(μmol/L)369.70 (304.55-442.30)355.05 (282.30-444.47)Cr (μmol/L)78.30 (67.30-93.85)79.95 (68.45-93.90)BUN (μmol/L)7.12±6.387.77±4.57eGFR(mL/min/1.73m²)81.12 (61.10-92.44)78.88 (60.25-85.46)Serum lipids and glucose70.70 (mmol/L)3.74(2.96-4.52)3.72 (2.97-4.19)TG (mmol/L)1.25 (0.92-1.80)1.49 (0.35-2.42)HDL-C (mmol/L)1.06 (0.870-1.26)0.915 (0.770-1.071)LDL-C (mmol/L)2.31 (1.74-2.96)2.215 (1.780-2.59)Glu (mmol/L)4.74 (4.20-5.52)5.32 (4.32-6.48)TyG index6.95(6.47-7.36)7.15(6.49-7.96)HbA1c (%)6.30(5.90-6.75)6.48 (6.075-7.00)Basic parametersHR (mmHg)72.54±14.5076.20±22.01		1.11±0.49	1.08±0.30	0.843	
Cr (μmol/L)       78.30 (67.30-93.85)       79.95 (68.45-93.90)         BUN (μmol/L)       7.12±6.38       7.77±4.57         eGFR(mL/min/1.73m²)       81.12 (61.10-92.44)       78.88 (60.25-85.46)         Serum lipids and glucose         TC (mmol/L)       3.74(2.96-4.52)       3.72 (2.97-4.19)         TG (mmol/L)       1.25 (0.92-1.80)       1.49 (0.35-2.42)         HDL-C (mmol/L)       1.06 (0.870-1.26)       0.915 (0.770-1.071)         LDL-C (mmol/L)       2.31 (1.74-2.96)       2.215 (1.780-2.59)         Glu (mmol/L)       4.74 (4.20-5.52)       5.32 (4.32-6.48)         TyG index       6.95(6.47-7.36)       7.15(6.49-7.96)         HbA1c (%)       6.30(5.90-6.75)       6.48 (6.075-7.00)         Basic parameters         HR (mmHg)       72.54±14.50       76.20±22.01		2(0.70 (204.55, 442.20)	255.05 (202.20.444.45)	0.660	
BUN (μmoI/L)       7.12±6.38       7.77±4.57         eGFR(mL/min/1.73m²)       81.12 (61.10-92.44)       78.88 (60.25-85.46)         Serum lipids and glucose         TC (mmol/L)       3.74(2.96-4.52)       3.72 (2.97-4.19)         TG (mmol/L)       1.25 (0.92-1.80)       1.49 (0.35-2.42)         HDL-C (mmol/L)       1.06 (0.870-1.26)       0.915 (0.770-1.071)         LDL-C (mmol/L)       2.31 (1.74-2.96)       2.215 (1.780-2.59)         Glu (mmol/L)       4.74 (4.20-5.52)       5.32 (4.32-6.48)         TyG index       6.95(6.47-7.36)       7.15(6.49-7.96)         HbA1c (%)       6.30(5.90-6.75)       6.48 (6.075-7.00)         Basic parameters         HR (mmHg)       72.54±14.50       76.20±22.01	. ,	,	,	0.668	
eGFR(mL/min/1.73m²)       81.12 (61.10-92.44)       78.88 (60.25-85.46)         Serum lipids and glucose         TC (mmol/L)       3.74(2.96-4.52)       3.72 (2.97-4.19)         TG (mmol/L)       1.25 (0.92-1.80)       1.49 (0.35-2.42)         HDL-C (mmol/L)       1.06 (0.870-1.26)       0.915 (0.770-1.071)         LDL-C (mmol/L)       2.31 (1.74-2.96)       2.215 (1.780-2.59)         Glu (mmol/L)       4.74 (4.20-5.52)       5.32 (4.32-6.48)         TyG index       6.95(6.47-7.36)       7.15(6.49-7.96)         HbA1c (%)       6.30(5.90-6.75)       6.48 (6.075-7.00)         Basic parameters         HR (mmHg)       72.54±14.50       76.20±22.01		· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	0.818	
Serum lipids and glucose         TC (mmol/L)       3.74(2.96-4.52)       3.72 (2.97-4.19)         TG (mmol/L)       1.25 (0.92-1.80)       1.49 (0.35-2.42)         HDL-C (mmol/L)       1.06 (0.870-1.26)       0.915 (0.770-1.071)         LDL-C (mmol/L)       2.31 (1.74-2.96)       2.215 (1.780-2.59)         Glu (mmol/L)       4.74 (4.20-5.52)       5.32 (4.32-6.48)         TyG index       6.95(6.47-7.36)       7.15(6.49-7.96)         HbA1c (%)       6.30(5.90-6.75)       6.48 (6.075-7.00)         Basic parameters         HR (mmHg)       72.54±14.50       76.20±22.01				0.645	
TC (mmol/L) 3.74(2.96-4.52) 3.72 (2.97-4.19) TG (mmol/L) 1.25 (0.92-1.80) 1.49 (0.35-2.42) HDL-C (mmol/L) 1.06 (0.870-1.26) 0.915 (0.770-1.071) LDL-C (mmol/L) 2.31 (1.74-2.96) 2.215 (1.780-2.59) Glu (mmol/L) 4.74 (4.20-5.52) 5.32 (4.32-6.48) TyG index 6.95(6.47-7.36) 7.15(6.49-7.96) HbA1c (%) 6.30(5.90-6.75) 6.48 (6.075-7.00) Basic parameters HR (mmHg) 72.54±14.50 76.20±22.01		81.12 (61.10-92.44)	78.88 (60.25-85.46)	0.445	
TG (mmol/L)       1.25 (0.92-1.80)       1.49 (0.35-2.42)         HDL-C (mmol/L)       1.06 (0.870-1.26)       0.915 (0.770-1.071)         LDL-C (mmol/L)       2.31 (1.74-2.96)       2.215 (1.780-2.59)         Glu (mmol/L)       4.74 (4.20-5.52)       5.32 (4.32-6.48)         TyG index       6.95(6.47-7.36)       7.15(6.49-7.96)         HbA1c (%)       6.30(5.90-6.75)       6.48 (6.075-7.00)         Basic parameters         HR (mmHg)       72.54±14.50       76.20±22.01		3 74(2 96-4 52)	3 72 (2 97-4 19)	0.597	
HDL-C (mmol/L)       1.06 (0.870-1.26)       0.915 (0.770-1.071)         LDL-C (mmol/L)       2.31 (1.74-2.96)       2.215 (1.780-2.59)         Glu (mmol/L)       4.74 (4.20-5.52)       5.32 (4.32-6.48)         TyG index       6.95(6.47-7.36)       7.15(6.49-7.96)         HbA1c (%)       6.30(5.90-6.75)       6.48 (6.075-7.00)         Basic parameters         HR (mmHg)       72.54±14.50       76.20±22.01	,	· · · · · · · · · · · · · · · · · · ·	, ,	0.541	
LDL-C (mmol/L)       2.31 (1.74-2.96)       2.215 (1.780-2.59)         Glu (mmol/L)       4.74 (4.20-5.52)       5.32 (4.32-6.48)         TyG index       6.95(6.47-7.36)       7.15(6.49-7.96)         HbA1c (%)       6.30(5.90-6.75)       6.48 (6.075-7.00)         Basic parameters         HR (mmHg)       72.54±14.50       76.20±22.01		· · · · · · · · · · · · · · · · · · ·		0.033	
Glu (mmol/L)       4.74 (4.20-5.52)       5.32 (4.32-6.48)         TyG index       6.95(6.47-7.36)       7.15(6.49-7.96)         HbA1c (%)       6.30(5.90-6.75)       6.48 (6.075-7.00)         Basic parameters         HR (mmHg)       72.54±14.50       76.20±22.01		,	,	0.433	
TyG index       6.95(6.47-7.36)       7.15(6.49-7.96)         HbA1c (%)       6.30(5.90-6.75)       6.48 (6.075-7.00)         Basic parameters       HR (mmHg)       72.54±14.50       76.20±22.01	,	· · · · · · · · · · · · · · · · · · ·	,	0.126	
HbA1c (%) 6.30(5.90-6.75) 6.48 (6.075-7.00)  Basic parameters  HR (mmHg) 72.54±14.50 76.20±22.01		,		0.126	
Basic parameters           HR (mmHg)         72.54±14.50         76.20±22.01			<u> </u>	0.202	
HR (mmHg) 72.54±14.50 76.20±22.01		0.30(3.90-0.73)	0.48 (0.073-7.00)	0.220	
· · · ·	*	<b>50.54</b> , 54.50	<b>5</b> (00 00 01	0.50.5	
SBP (mmHg) 127.55±19.24 125.92±17.63	· •			0.285	
	P (mmHg)	127.55±19.24	125.92±17.63	0.702	

DBP (mmHg)	72.67±13.06	72.03±12.91	0.828

HDL-C showed significant difference between PH and non-PH groups. However, the TyG index showed no significant differences between them.

15 16

17

Table 4 Relationship between sPAP and other paramters

Table 4 Relationship between sPA	Correlation coefficient r	P value
Demographic data		
Age (years)	0.071	0.264
BMI $((kg/m^2))$	-0.009	0.884
Echocardiographic parameters		
LAD (mm)	0.110	0.083
LVDD (mm)	0.060	0.347
LVEF (%)	0.071	0.268
SV (ml)	0.032	0.618
RAD (mm)	0.095	0.138
RVD (mm)	0.092	0.149
FS (%)	0.069	0.283
TRA (cm <sup>2</sup> )	0.151	0.017
TRV (m/s)	0.156	0.014
Biomarkers		
BNP (pg/ml)	0.113	0.078
TNI (ng/ml)	-0.041	0.519
MYO (ng/ml)	0.109	0.089
CK-MB (ng/ml)	0.040	0.531
Electrolytes Mg <sup>2+</sup> (mmol/L)	0.034	0.490
K <sup>+</sup> (mmol/L)	-0.006	0.924
Ca <sup>2+</sup> (mmol/L)	0.049	0.440
Na <sup>+</sup> (mmol/L)	-0.059	0.352
Cl (mmol/L)	-0.074	0.247
$TCO_2 (mmol/L)$	0.061	0.338
P (mmol/L)	-0.064	0.318
Renal function		
UA(μmoI/L)	-0.003	0.968
Cr (µmoI/L)	-0.010	0.880
BUN (µmoI/L)	0.029	0.650
eGFR(mL/min/1.73m <sup>2</sup> )	0.053	0.405
Serum lipids and glucose		
TC (mmol/L)	-0.089	0.166
TG (mmol/L)	-0.105	0.099
HDL-C (mmol/L)	-0.041	0.526
LDL-C (mmol/L)	-0.117	0.066
Glu (mmol/L)	-0.024	0.703
TyG index	-0.095	0.136

HbA1c (%)	-0.027	0.67 <b>&amp;</b> 0
Basic parameters		
HR (bpm)	-0.034	0.592
SBP (mmHg)	-0.070	0.271
DBP (mmHg)	-0.087	0.173

Baselines of TRA and TRV were closely correlated to the followed-up sPAP.

21

Table 5 Univariate logistics regression for PH

					95%CI
Demographic data	β	р	OR		
Age (years)	0.025	0.214	1.025	0.986	1.066
BMI (kg/m2)	-0.087	0.204	0.917	0.802	1.048
Gender, female, n (%)	-0.263	0.582	0.769	0.301	1.961
smoking, n (%)	-0.485	0.310	0.616	0.242	1.569
Drinking n (%)	-0.314	0.626	0.730	0.206	2.587
Cerebral infarction history	0.991	0.033	2.694	1.085	6.690
Hypertension n (%)	-0.016	0.973	0.984	0.396	2.446
T2DM, n (%)	-0.058	0.907	0.943	0.353	2.518
Meditation					
CCB, n (%)	0.163	0.761	1.176	0.412	3.359
ACEI/ARB, n (%)	0.102	0.839	1.107	0.415	2.953
β-blocker, n (%)	-0.363	0.437	0.696	0.278	1.738
Diuretic, n (%)	0.029	0.957	1.029	0.362	2.928
Echocardiographic parameters					
LAD (mm)	0.074	0.095	1.077	0.987	1.174
LVDD (mm)	0.035	0.291	1.035	0.971	1.105
LVEF (%)	-0.017	0.396	0.983	0.944	1.023
SV (ml)	0.009	0.456	1.009	0.986	1.032
RAD (mm)	0.055	0.172	1.057	0.976	1.144
RVD (mm)	0.073	0.227	1.076	0.955	1.212
FS (%)	-0.029	0.378	0.972	0.912	1.036
TRA (cm <sup>2</sup> )	0.111	0.476	1.117	0.823	1.516
TRV (m/s)	0.001	0.818	1.000	0.997	1.004
Biomarkers					
BNP (pg/ml)	0.001	0.357	1.000	1.000	1.001
TNI (ng/ml)	-0.215	0.680	0.807	0.290	2.243
MYO (ng/ml)	0.007	0.024	1.007	1.001	1.013
CK-MB (ng/ml)	-0.083	0.642	0.920	0.649	1.306
Electrolytes	2 = 2 = 2	0.60.5		0.00-	0.4.555
Mg <sup>2+</sup> (mmol/L)	-0.796	0.696	0.451	0.008	24.579
$K^+$ (mmol/L)	-0.185	0.639	0.831	0.383	1.803
Ca <sup>2+</sup> (mmol/L) Na <sup>+</sup> (mmol/L)	-0.281 0.014	0.825 0.639	0.755 1.014	0.063 0.957	9.066 1.075
Na (mmol/L) Cl <sup>-</sup> (mmol/L)	-0.031	0.639	0.970	0.957	1.073
$\Gamma(O_2(\text{mmol/L}))$	0.011	0.733	1.011	0.884	1.076
P (mmol/L)	-0.123	0.733	0.884	0.261	2.995
Renal function	0.123	0.011	0.001	0.201	2.,,,,
UA(μmoI/L)	0.001	0.829	1.000	0.997	1.004
Cr (µmoI/L)	-0.004	0.581	0.996	0.984	1.009
BUN (μmoI/L)	0.013	0.649	1.013	0.958	1.070
eGFR(mL/min/1.73m <sup>2</sup> )	-0.002	0.829	0.998	0.978	1.018

TC (mmol/L)	-0.185	0.391	0.831	0.545	1.268	
TG (mmol/L)	0.304	0.015	1.355	1.062	1.730	
HDL-C (mmol/L)	-1.744	0.065	0.175	0.027	1.115	
LDL-C (mmol/L)	-0.315	0.275	0.730	0.414	1.285	
Glu (mmol/L)	0.180	0.066	1.198	0.988	1.451	
TyG index	0.628	0.005	2.389	1.308	4.363	
HbA1c (%)	0.288	0.071	1.334	0.975	1.825	
Basic parameters						
HR (bpm)	0.014	0.287	1.014	0.989	1.039	
SBP (mmHg)	-0.005	0.701	0.995	0.972	1.019	
DBP (mmHg)	-0.004	0.827	0.996	0.963	1.030	

Primarily screen for the predictors for PH.

## Table 6 Adjusted logistic regression for PH in CAD patients after PCI treatments

	β	p	OR	(	95%CI
Cerebral infarction history	0.990	0.039	2.690	1.054	6.871
TyG index	0.636	0.048	1.889	1.006	3.546
MYO	0.006	0.044	1.006	1.000	1.012

Three of the above parameters were independent predictors of PH

30

31 32

33